Citadel Advisors
ALLO icon

Citadel Advisors’s Allogene Therapeutics ALLO Stock Holding History

Citadel Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.1K Buy
32,000
+13,200
+70% +$26.5K ﹤0.01% 12193
2025
Q4 		$25.8K Sell
18,800
-1,800
-9% -$2.37K ﹤0.01% 12274
2025
Q3 		$25.5K Sell
20,600
-100
-0.5% -$119 ﹤0.01% 12439
2025
Q2 		$23.4K Sell
20,700
-4,200
-17% -$5.58K ﹤0.01% 12068
2025
Q1 		$36.4K Buy
24,900
+10,000
+67% +$18.9K ﹤0.01% 12626
2024
Q4 		$31.7K Sell
14,900
-25,000
-63% -$61.7K ﹤0.01% 12814
2024
Q3 		$112K Sell
39,900
-2,500
-6% -$6.67K ﹤0.01% 10972
2024
Q2 		$98.8K Buy
42,400
+27,500
+185% +$81.1K ﹤0.01% 10932
2024
Q1 		$66.6K Sell
14,900
-28,400
-66% -$119K ﹤0.01% 11875
2023
Q4 		$139K Buy
43,300
+1,600
+4% +$4.54K ﹤0.01% 10507
2023
Q3 		$132K Buy
41,700
+8,000
+24% +$35.1K ﹤0.01% 10536
2023
Q2 		$167K Buy
33,700
+8,100
+32% +$43.8K ﹤0.01% 10156
2023
Q1 		$126K Buy
25,600
+9,200
+56% +$59K ﹤0.01% 10911
2022
Q4 		$103K Sell
16,400
-1,400
-8% -$13K ﹤0.01% 11174
2022
Q3 		$192K Buy
+17,800
New +$242K ﹤0.01% 10441
2022
Q2 		– Sell
-19,800
Closed -$180K – 12792
2022
Q1 		$180K Sell
19,800
-10,900
-36% -$114K ﹤0.01% 11652
2021
Q4 		$458K Buy
30,700
+18,500
+152% +$326K ﹤0.01% 9910
2021
Q3 		$314K Sell
12,200
-11,500
-49% -$273K ﹤0.01% 10971
2021
Q2 		$618K Sell
23,700
-16,300
-41% -$465K ﹤0.01% 9544
2021
Q1 		$1.41M Buy
40,000
+3,300
+9% +$111K ﹤0.01% 7253
2020
Q4 		$926K Buy
36,700
+28,100
+327% +$916K ﹤0.01% 6955
2020
Q3 		$324K Sell
8,600
-10,000
-54% -$377K ﹤0.01% 8003
2020
Q2 		$796K Sell
18,600
-2,700
-13% -$97.6K ﹤0.01% 6248
2020
Q1 		$414K Buy
21,300
+13,100
+160% +$312K ﹤0.01% 6765
2019
Q4 		$213K Buy
+8,200
New +$226K ﹤0.01% 8075

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors's ALLO Position: Q1 2026 in Review

Citadel Advisors reduced its Allogene Therapeutics (ALLO) stake by 44% in Q1 2026, selling an estimated $10.7M and leaving 6,793,620 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2564.

Citadel Advisors first reported a position in ALLO in Q4 2018 and has held it in 30 quarters since. The position peaked at $35.4M in Q4 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Citadel Advisors held 6,793,620 shares of Allogene Therapeutics worth $16.6M as of Q1 2026.
  • Citadel Advisors sold 5,317,800 Allogene Therapeutics shares in Q1 2026, an estimated $10.7M.
  • Allogene Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2564 holding.
  • Citadel Advisors first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • Citadel Advisors's Allogene Therapeutics position peaked at $35.4M in Q4 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.